Lapatinib benefits found for HER2-positive early-stage patients

Women with early-stage, HER2-positive breast cancer who are unable to use trastuzumab may benefit from adjuvant lapatinib treatment, suggest phase III trial findings published in Lancet Oncology.
Source: MedWire News - Breast Cancer - Category: Cancer & Oncology Source Type: news